Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 135 participants.

Also called NCT07441200

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 135 participants (planned count) (from the registry)
Sponsor
NS Pharma, Inc. (from the registry)
Registry
  • NCT NCT07441200
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07441200. Randomized; triple masking; primary purpose treatment. Start 2026-09-29 (actual); primary completion 2028-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
NS-863 Low Dose
Intervention (Drug)
NS-863 High Dose
Intervention (Drug)
NS-863 Placebo
Lead sponsor
NS Pharma, Inc. (class: industry)
Collaborator
Nippon Shinyaku Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07441200
Content hash
9da380f83e0d9dc692c4d73af1b6dfbc40608a84103949acb19ba6658de893a9